The antifungal protein NFAP2 has low potential to trigger resistance development in .

Due to the increase in the number of drug-resistant strains, new antifungal compounds with limited potential for the development of resistance are urgently needed. NFAP2, an antifungal protein (AFP) secreted by () , is a promising candidate. We investigated the ability of to develop resistance to NFAP2 in a microevolution experiment compared with generic fluconazole (FLC).